Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 112Lymphoma, Large B-Cell, Diffuse 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Leukemia 47Burkitt Lymphoma 45Lymphoma, Non-Hodgkin 35Lymphoma, Mantle-Cell 28Lymphoma, Follicular 27Hodgkin Disease 22Neuroblastoma 19Central Nervous System Neoplasms 19Sarcoma 18Lymphoma, B-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, T-Cell, Peripheral 11Lymphoma, Large-Cell, Anaplastic 11Neoplasms 10Multiple Myeloma 10Dendritic Cell Sarcoma, Interdigitating 10Sarcoma, Ewing 9Rhabdomyosarcoma 9Retinoblastoma 9Medulloblastoma 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Biphenotypic, Acute 8Recurrence 7Neuroectodermal Tumors, Primitive, Peripheral 7Lymphoma, T-Cell 7HIV Infections 7

Interventions

Cyclophosphamide 5Rituximab 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2blinatumomab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2pembrolizumab 1Vorinostat 1CLR1404 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoproliferative Disorders × Vincristine × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡